Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy

Archive ouverte

Saoudi, Amel | Zarrouki, Faouzi | Sebrié, Catherine | Izabelle, Charlotte | Goyenvalle, Aureĺie | Vaillend, Cyrille

Edité par CCSD ; Cambridge Company of Biologists -

International audience. The exon-52-deleted mdx52 mouse is a critical model of Duchenne muscular dystrophy (DMD), as it features a deletion in a hotspot region of the DMD gene, frequently mutated in patients. Deletion of exon 52 impedes expression of several brain dystrophins (Dp427, Dp260 and Dp140), thus providing a key model for studying the cognitive impairment associated with DMD and testing rescuing strategies. Here, using in vivo magnetic resonance imaging and neurohistology, we found no gross brain abnormalities in mdx52 mice, suggesting that the neural dysfunctions in this model are likely at the level of brain cellular functionalities. Then, we investigated emotional behavior and fear learning performance of mdx52 mice compared to mdx mice that only lack Dp427 to focus on behavioral phenotypes that could be used in future comparative preclinical studies. mdx52 mice displayed enhanced anxiety and a severe impairment in learning an amygdala-dependent Pavlovian association. These replicable behavioral outcome measures are reminiscent of the internalizing problems reported in a quarter of DMD patients, and will be useful for preclinical estimation of the efficacy of treatments targeting brain dysfunctions in DMD.

Suggestions

Du même auteur

Impact of distinct dystrophin gene mutations on behavioral phenotypes of Duchenne muscular dystrophy

Archive ouverte | Saoudi, Amel | CCSD

International audience. The severity of brain comorbidities in Duchenne muscular dystrophy (DMD) depends on the mutation position within the DMD gene and differential loss of distinct brain dystrophin isoforms (i.e....

AAV-Mediated Restoration of Dystrophin-Dp71 in the Brain of Dp71-Null Mice: Molecular, Cellular and Behavioral Outcomes

Archive ouverte | Vacca, Ophélie | CCSD

International audience. A deficiency in the shortest dystrophin-gene product, Dp71, is a pivotal aggravating factor for intellectual disabilities in Duchenne muscular dystrophy (DMD). Recent advances in preclinical ...

Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy.

Archive ouverte | Vianello, Sara | CCSD

International audience. As a strategy to treat Duchenne muscular dystrophy, we used arginine butyrate, which combines two pharmacological activities: nitric oxide pathway activation, and histone deacetylase inhibiti...

Chargement des enrichissements...